Sunday, 18 July 2010

Abstract

Background: Erythropoietin (Epo) can reduce the infarct size and have a cardio protective effect in animal models of myocardial infarction(MI). We hypotezed that higher dose of Epo can reduce myocardial infarct size more efficiently. Method: We compared the impact of conventional and higher dose of single systemic administration of recombinant human Epo alpha (5000U/kg versus 10.000 U/kg i.p.) on left ventricular (LV) infarct size immediately after the induction of a myocardial infarction (MI) bypermanent ligation of the left descending coronary artery. Serum epolevels, immunohistochemistry (Epo-R, Caspase 3, HIF) and electron microscopy were studied. Results: Injection of 5.000 U/kg Epo alpha (Figure-middle) reduces theinfact size compared to the control group (Figure-top). However,10000U/kg Epo (Figure-buttom) showed no additional benefit over5000 U/kg Epo i.p.after coronary ligation (p:0.7). (PDF) No additional benefit from higher dose erythropoietin to reduce infarct size after coronary artery ligation in wistar rats. Available from: https://www.researchgate.net/publication/345389638_No_additional_benefit_from_higher_dose_erythropoietin_to_reduce_infarct_size_after_coronary_artery_ligation_in_wistar_rats [accessed Nov 07 2020].